• 1
    Lee DM, Weinblatt ME.Rheumatoid arthritis.Lancet2001;358:90311.
  • 2
    Pincus T, Callahan LF.Taking mortality in rheumatoid arthritis seriously: predictive markers, socioeconomic status and comorbidity.J Rheumatol1986;13:8415.
  • 3
    Badley EM, Rasooly I, Webster GK.Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability, and health care utilization: findings from the 1990 Ontario Health Survey.J Rheumatol1994;21:50514.
  • 4
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al.Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.Arthritis Rheum2005;52:338190.
  • 5
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al.Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.Lancet2004;364:2639.
  • 6
    Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al.The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials.Arthritis Rheum1993;36:72940.
  • 7
    Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al.Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).Ann Rheum Dis2007;66:14439.
  • 8
    Fransen J, Moens HB, Speyer I, van Riel PL.Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial.Ann Rheum Dis2005;64:12948.
  • 9
    Schipper LG, van Hulst LT, Grol R, van Riel PL, Hulscher ME, Fransen J.Meta-analysis of tight control strategies in rheumatoid arthritis: protocolized treatment has additional value with respect to the clinical outcome.Rheumatology (Oxford)2010;49:215464.
  • 10
    Fries JF, Spitz P, Kraines RG, Holman HR.Measurement of patient outcome in arthritis.Arthritis Rheum1980;23:13745.
  • 11
    Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D.The Work Limitations Questionnaire.Med Care2001;39:7285.
  • 12
    Hyrich KL, Watson KD, Silman AJ, Symmons DP.Predictors of response to anti-TNF therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.Rheumatology (Oxford)2006;45:155865.
  • 13
    Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al.Etanercept treatment in adults with established rheumatoid arthritis: 7 years clinical experience.J Rheumatol2006;33:85461.
  • 14
    Barra L, Pope J, Payne M.Real world anti-TNF treatment in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve HAQ.J Rheumatol2009;36:14218.
  • 15
    Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, on behalf of the Swiss Clinical Quality Management Physicians.Comparison of drug retention rates and causes of drug discontinuation between anti–tumor necrosis factor agents in rheumatoid arthritis.Arthritis Rheum2009;61:5608.
  • 16
    Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, et al.Concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.Ann Rheum Dis2011;70:5839.
  • 17
    Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al.Treating rheumatoid arthritis to target: recommendations of an international task force.Ann Rheum Dis2010;69:6317.
  • 18
    Zhang J, Shan Y, Reed G, Kremer J, Greenberg J, Baumgartner S, et al.Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large US cohort.Arthritis Care Res (Hoboken)2011;63:16729.